Drolet M, Bénard E, Pérez N, et al. - Through a systematic review and meta-analysis of the population-level influence of vaccinating females against human papillomavirus on human papillomavirus (HPV) infections, anogenital wart diagnoses, and cervical intraepithelial neoplasia grade 2+ (CIN2+), researchers summarized the most recent evidence about the efficiency of HPV vaccines in real-world settings, and quantified the influence of multiple age-cohort vaccination. A total of 1,702 potentially eligible articles and 65 articles in 14 high-income countries were included. The prevalence of HPV 16 and 18 reduced significantly by 83% and 66% among girls aged 13–19 years and among women aged 20–24 years, respectively, following 5–8 years of vaccination. Among girls aged 13–19 years, the prevalence of HPV 31, 33, and 45 reduced significantly by 54%. Anogenital wart diagnoses reduced significantly by 67%, 54%, and 31% among girls aged 15–19 years, among women aged 20–24 years, and among women aged 25–29 years, respectively. Among boys aged 15–19 years and among men aged 20–24 years, anogenital wart diagnoses reduced significantly by 48% and 32%, respectively. Following 5–9 years of vaccination, CIN2+ decreased significantly among screened girls aged 15–19 years and among women aged 20–24 years by 51% and 31%, respectively. Hence, the substantial influence of HPV vaccination programs on HPV infections and CIN2+ among girls and women, and on anogenital warts diagnoses among girls, women, boys, and men was evident. Furthermore, programs with multi-cohort vaccination and high vaccination coverage had a higher direct influence and herd impact.